1. Aden U, Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraceotion 1984; 58: 75–81.
2. Cosson M, Querleu D, Donnez J et al. Dienogest is as effective as triptorelin in the threatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002; 77 (44): 684–92.
3. Heindrichs WL. Prevention of endometriosis sings symptoms. US patent 6265393 B 1, filed 198, issued 2001.
4. Kistner RW. Use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol 1956; 75: 264–78.
5. Morre C, Kohler G, Muller A. The treatment of endometriosis with dienogest. Drug Today 1999; 35: 41–52.
6. Nikschick S, Kohler G, Mannchen E. Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest. Exp Clin Endocrinol 1989; 94 (1/2): 211–4.
7. Sulak PG, Gressman BE, Waldrop E et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179–83.
8. Varcellini P, De Giorgi O, Mosconi P et al. Cytproterone acetate versus a continuous monophasic oral contraceptives in the treatment of recurrent pelvic pain after concervative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52–61.
9. Zimmermann T, Dietrich H, Wisser KH, Hoffman H. Efficacy and tolerability of the dienogest – containing oral contraceptive Valette. Drugs Today 1999; 35 (Suppl. C): 79–87.
Авторы
В.Н.Прилепская
ГУ Научный центра акушерства, гинекологии и перинатологии (дир. – акад. РАМН В.И.Кулаков) РАМН, Москва